Good Clinical Practice (GCP)
Full course · Clinical Research Foundations
Free Lesson Preview
This lesson is part of a complete GCP track — 2 courses, quizzes, a final exam, and a free verifiable credential. The optional $29 PDF certificate is recognized by 18+ trial sponsors.
Start learning for freeAlready enrolled? Sign in
What happens when a clinical trial ends, including final visits, follow-up procedures, learning about results, and the lasting impact of research participation.
What you will learn5 objectives
By the end of this lesson, you will be able to:
When a participant reaches the end of their scheduled time in a clinical trial, they typically attend a final visit designed to accomplish several important goals. This visit ensures a safe transition, gathers final data, and provides closure for both the participant and the research team.
The end-of-study visit mirrors many of the assessments from earlier visits, but with a specific purpose: establishing the participant's status at the conclusion of their involvement. Common components include:
Physical examination. A physician assesses the participant's overall health, paying particular attention to any symptoms or conditions that developed during the study. This examination becomes part of the final safety record.
Blood and urine samples may be collected to assess organ function and look for any changes since the study began. These results help determine whether the study treatment had effects that require ongoing monitoring.
Progress saves itself — finish reading and this lesson completes
Review of symptoms and adverse events. The research team carefully documents any symptoms the participant is experiencing, whether related to the study or not. Any ongoing adverse events are recorded with plans for follow-up.
Final efficacy assessments. If the study measured outcomes like blood pressure, pain scores, or disease activity, these are measured one final time. These data points complete the picture of how the participant responded during the trial.
Participants who received study medication, devices, or other supplies must return any unused items at the final visit. This process, called investigational product accountability, serves several purposes.
First, it helps ensure safety. Study medications should not remain in homes where they might be taken incorrectly or accessed by others. Second, it helps researchers track how much medication participants actually used, which is important for interpreting results. If a participant returns a half-full bottle of pills, researchers can account for doses that may have been missed.
The return process is handled discreetly and without judgment. Researchers understand that life happens, and imperfect adherence is common. What matters is honest reporting so the data accurately reflect what occurred.
Not all symptoms resolve when participation ends. At the end-of-study visit, the research team carefully assesses any ongoing issues and creates a plan for addressing them.
Consider a participant in a trial for migraine prevention at an academic medical center. Throughout the study, he had experienced occasional dizziness, a known possible side effect of the study drug. At his final visit, the dizziness was still present. The research team documented this as an ongoing adverse event and arranged for follow-up testing with his regular physician. They also provided a letter describing his trial participation for his medical records.
This handoff is essential. The participant's regular healthcare providers need to know what happened during the trial so they can provide appropriate ongoing care.
